↓ Skip to main content

Cochrane Database of Systematic Reviews

Omalizumab for asthma in adults and children

Overview of attention for article published in Cochrane database of systematic reviews, January 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
1 news outlet
policy
1 policy source
twitter
67 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
413 Dimensions

Readers on

mendeley
490 Mendeley
citeulike
2 CiteULike
Title
Omalizumab for asthma in adults and children
Published in
Cochrane database of systematic reviews, January 2014
DOI 10.1002/14651858.cd003559.pub4
Pubmed ID
Authors

Rebecca Normansell, Samantha Walker, Stephen J Milan, E. Haydn Walters, Parameswaran Nair

Abstract

Asthma is a respiratory (airway) condition that affects an estimated 300 million people worldwide and is associated with significant morbidity and mortality. Omalizumab is a monoclonal antibody that binds and inhibits free serum immunoglobulin E (IgE). It is called an 'anti-IgE' drug. IgE is an immune mediator involved in clinical manifestations of asthma. A recent update of National Institute for Health and Care Excellence (NICE) guidance in 2013 recommends omalizumab for use as add-on therapy in adults and children over six years of age with inadequately controlled severe persistent allergic IgE-mediated asthma who require continuous or frequent treatment with oral corticosteroids.

Twitter Demographics

The data shown below were collected from the profiles of 67 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 490 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 <1%
Japan 2 <1%
Tunisia 1 <1%
Mexico 1 <1%
South Africa 1 <1%
Ecuador 1 <1%
Unknown 482 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 80 16%
Student > Bachelor 66 13%
Researcher 63 13%
Student > Ph. D. Student 53 11%
Student > Postgraduate 34 7%
Other 116 24%
Unknown 78 16%
Readers by discipline Count As %
Medicine and Dentistry 231 47%
Nursing and Health Professions 32 7%
Agricultural and Biological Sciences 26 5%
Biochemistry, Genetics and Molecular Biology 20 4%
Psychology 15 3%
Other 66 13%
Unknown 100 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 52. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2021.
All research outputs
#521,810
of 18,233,205 outputs
Outputs from Cochrane database of systematic reviews
#1,186
of 11,813 outputs
Outputs of similar age
#7,497
of 278,576 outputs
Outputs of similar age from Cochrane database of systematic reviews
#16
of 170 outputs
Altmetric has tracked 18,233,205 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,813 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 170 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.